HemOncToday.com RSS Daily Feedhttp://www.HemOncToday.com/rssDisplay.aspxen-us09/03/2010The latest news and articles from the Endocrinology Today, leading publication on the web.Copyright 2008 HemOnc Today. All Rights Reserved.5ISAR REACT 3A: Lower dose unfractionated heparin led to decreased bleeding vs. higher dosehttp://www.HemOncToday.com/article.aspx?rid=68177Thu, 02 Sep 2010 16:33:00 GMTISAR REACT 3A: Lower dose unfractionated heparin led to decreased bleeding vs. higher dosehttp://www.HemOncToday.com/article.aspx?rid=68177Thu, 02 Sep 2010 16:33:00 GMTSurgery lowered risk for breast, ovarian cancer in women with <I>BRCA1</I> and <I>BRCA2 </I>mutations<A HREF="http://jama.ama-assn.org/cgi/content/abstract/304/9/967" TARGET="_new">Domchek SM. <CITE>JAMA</CITE>. 2010;doi:10.1001/jama.2010.1237</A>.http://www.HemOncToday.com/article.aspx?rid=68169Thu, 02 Sep 2010 12:04:00 GMTSurgery lowered risk for breast, ovarian cancer in women with <I>BRCA1</I> and <I>BRCA2 </I>mutations<A HREF="http://jama.ama-assn.org/cgi/content/abstract/304/9/967" TARGET="_new">Domchek SM. <CITE>JAMA</CITE>. 2010;doi:10.1001/jama.2010.1237</A>.http://www.HemOncToday.com/article.aspx?rid=68169Thu, 02 Sep 2010 12:04:00 GMT<I>BCR-ABL</I> transcript levels continued to decrease in patients with CML treated with imatinib therapy<A HREF="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-03-273979v1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Timothy+P.+Hughes&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT" TARGET="_new">Hughes TP. <CITE>Blood</CITE>. 2010;doi:10.1182/blood-2010-03-273979. </A>http://www.HemOncToday.com/article.aspx?rid=68146Wed, 01 Sep 2010 16:59:00 GMT<I>BCR-ABL</I> transcript levels continued to decrease in patients with CML treated with imatinib therapy<A HREF="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-03-273979v1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Timothy+P.+Hughes&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT" TARGET="_new">Hughes TP. <CITE>Blood</CITE>. 2010;doi:10.1182/blood-2010-03-273979. </A>http://www.HemOncToday.com/article.aspx?rid=68146Wed, 01 Sep 2010 16:59:00 GMTAdoptive cell therapy associated with complete, durable regression of melanoma brain metastases<P><B><A HREF="http://clincancerres.aacrjournals.org/content/early/2010/08/21/1078-0432.CCR-10-1507.abstract" TARGET="_new">Hong JJ. <CITE>Clin Cancer Res.</CITE> 2010;doi:10.1158/1078-0432.CCR-10-1507. </A></B></P>http://www.HemOncToday.com/article.aspx?rid=68088Wed, 01 Sep 2010 11:32:00 GMTAdoptive cell therapy associated with complete, durable regression of melanoma brain metastases<P><B><A HREF="http://clincancerres.aacrjournals.org/content/early/2010/08/21/1078-0432.CCR-10-1507.abstract" TARGET="_new">Hong JJ. <CITE>Clin Cancer Res.</CITE> 2010;doi:10.1158/1078-0432.CCR-10-1507. </A></B></P>http://www.HemOncToday.com/article.aspx?rid=68088Wed, 01 Sep 2010 11:32:00 GMTBone morphogenetic protein-2 higher in patients with multiple myeloma<P>Maes K. <I>Blood.</I> 2010;doi:10.1182/blood-2010-03-274571. </P>http://www.HemOncToday.com/article.aspx?rid=68066Tue, 31 Aug 2010 15:40:00 GMTBone morphogenetic protein-2 higher in patients with multiple myeloma<P>Maes K. <I>Blood.</I> 2010;doi:10.1182/blood-2010-03-274571. </P>http://www.HemOncToday.com/article.aspx?rid=68066Tue, 31 Aug 2010 15:40:00 GMT